Dr. Ulrich Keilholz
MD, Habilitation (Internal Medicine), Board Certified in Hematology & Medical Oncology
Director, Charité Comprehensive Cancer Center
corporate_fareCharité – Universitätsmedizin Berlin, Germany
Ulrich Keilholz
MD, Habilitation (Internal Medicine), Board Certified in Hematology & Medical Oncology
Prof. Dr. med. Ulrich Keilholz is a senior medical oncologist and Director of the Charité Comprehensive Cancer Center (CCCC) at Charité – Universitätsmedizin Berlin. With over 25 years of clinical and academic experience, he is one of Europe's leading specialists in melanoma, head and neck cancer, cancer immunotherapy, and precision oncology.
Prof. Keilholz trained at the Universities of Mainz, Heidelberg, and Lexington (USA), receiving his German medical licence in 1983 and completing his doctoral thesis at Heidelberg in 1984. He undertook a formative research fellowship under Prof. Steven A. Rosenberg at the National Cancer Institute in Bethesda in 1986, an early influence on his deep engagement with cancer immunology. He achieved board certifications in Internal Medicine (1990) and Hematology and Medical Oncology (1993), followed by a Habilitation in Internal Medicine at Heidelberg. His career at Charité spans senior academic and leadership positions, including Full Professor of Comprehensive Oncology and Director of the CCCC since 2013. Since 2023 he has also served as Co-Director and Speaker of the National Center for Tumor Diseases (NCT) Berlin branch. His research programme encompasses the design and leadership of more than 60 clinical trials across phases Ia to III, with a particular focus on translational cancer immunology and multilevel molecular cancer profiling.
CancerFax can coordinate medical-report review and second-opinion support for international patients seeking consultation with Prof. Keilholz at Charité Berlin, subject to hospital availability and case acceptance.
Why Consider Prof. Ulrich Keilholz?
Prof. Keilholz brings together decades of frontline clinical oncology, a major academic research programme, and leadership across Europe's top cancer organisations, making him a sought-after specialist for patients with melanoma, head and neck cancer, and complex immunotherapy cases.
Areas of Specialisation
Melanoma, head and neck cancer, immunotherapy, and precision oncology within a multidisciplinary academic cancer centre
Prof. Keilholz's clinical and research expertise spans medical oncology, melanoma, head and neck cancer, cancer immunotherapy, translational oncology, and precision molecular profiling. He leads multidisciplinary oncology programmes at Charité and the NCT Berlin.
Melanoma and Skin Cancer Oncology
Advanced medical oncology for melanoma including immunotherapy-based and targeted treatment strategies.
- arrow_rightPD-1 and CTLA-4 checkpoint inhibitor therapy for eligible patients
- arrow_rightCombination immunotherapy regimens based on pathology and staging
- arrow_rightTranslational research-informed treatment planning
- arrow_rightBRAF and MEK inhibitor therapy where molecularly indicated
- arrow_rightBiomarker-guided treatment selection
Head and Neck Cancer
Systemic oncology approaches for head and neck cancers within a multidisciplinary team framework.
- arrow_rightCheckpoint inhibitor therapy for eligible head and neck cancer patients
- arrow_rightChemotherapy and targeted therapy protocols
- arrow_rightMultidisciplinary treatment planning with surgical and radiation oncology teams
Cancer Immunotherapy and Translational Oncology
Clinical and translational immunology research translated into patient care pathways.
- arrow_rightTranslational research integrated into clinical trial design
- arrow_rightImmune biomarker evaluation for treatment eligibility
- arrow_rightMultilevel cancer profiling to inform treatment decisions
- arrow_rightMolecular cancer counselling for complex cases
Procedures Performed
Medical oncology services, immunotherapy protocols, and clinical trial-based care at Charité Berlin
Prof. Keilholz provides medical oncology treatment planning and delivery, with a particular focus on immunotherapy, targeted therapy, and clinical trial participation for melanoma, head and neck cancer, and sarcoma.
Medical Oncology Treatment Planning
Medical OncologyComprehensive treatment planning for solid tumours including melanoma, head and neck cancers, and sarcoma within a multidisciplinary oncology team.
Immunotherapy and Targeted Therapy
Targeted TherapyCheckpoint inhibitor and targeted molecular therapy approaches for melanoma and head and neck cancer patients with appropriate biomarker profiles.
Clinical Trial Participation
Complex DiseaseAccess to phase Ia–III clinical trials in melanoma, head and neck cancer, and immuno-oncology through Charité and the NCT Berlin.
Second Opinion Consultation
Second OpinionExpert second-opinion review of oncology cases in melanoma, head and neck cancer, and sarcoma, accessible to international patients through CancerFax.
Research & Publications
Melanoma immunotherapy, head and neck cancer, translational oncology, and clinical trial leadership
Prof. Keilholz has an extensive publication record in melanoma, head and neck cancer, cancer immunology, and precision oncology, with contributions to journals including the Journal of Clinical Oncology, The Lancet, Annals of Oncology, Nature Communications, and JCO Precision Oncology. His research programme has included the design of 35 clinical trials from phase Ia to III and principal-investigator roles in more than 25 further trials.
Prof. Keilholz's full list of publications is available via the Charité and Berlin School of Integrative Oncology faculty pages.
Education & Training
Prof. Keilholz completed medical training across Germany and the United States, achieving board certifications in Internal Medicine and Haematology/Medical Oncology and a Habilitation in Internal Medicine at the University of Heidelberg.
Clinical Experience
Prof. Keilholz has held senior clinical, academic, and leadership positions in Germany for over three decades, progressing from attending physician in Heidelberg to Director of the Charité Comprehensive Cancer Center and Co-Director of the National Center for Tumor Diseases Berlin branch.
Languages & International
Prof. Keilholz consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients whose primary language is neither English nor German.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Ulrich Keilholz
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Ulrich Keilholz's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Ulrich Keilholz's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Ulrich Keilholz before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Ulrich Keilholz's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Ulrich Keilholz's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Ulrich Keilholz's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Ulrich Keilholz
Prof. Keilholz is a medical oncologist specialising in melanoma, head and neck cancer, cancer immunotherapy, translational oncology, and precision oncology. He directs the Charité Comprehensive Cancer Center in Berlin.
Prof. Keilholz is based at Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals, where he serves as Director of the Charité Comprehensive Cancer Center.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Keilholz at Charité Berlin, subject to hospital availability and case acceptance.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, treatment history, and relevant test results. The final consultation format and timeline depend on the doctor's schedule and institutional processes at Charité.
Prof. Keilholz's primary clinical and research focus includes melanoma (including uveal melanoma), head and neck cancer, and sarcoma. He also works broadly in cancer immunotherapy and precision oncology for solid tumours.
Yes. Prof. Keilholz has designed 35 clinical trials from phase Ia to III and has served as principal investigator in more than 25 additional national and international trials. Eligibility for trial participation depends on individual patient assessment at Charité.
Submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare the case summary, and coordinate the next steps with Charité, subject to availability and case suitability.
Connect with Ulrich Keilholz Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.